Y Intercept Hong Kong Ltd Invests $210,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Y Intercept Hong Kong Ltd acquired a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Rating) in the second quarter, HoldingsChannel reports. The fund acquired 18,422 shares of the company’s stock, valued at approximately $210,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ALLO. US Bancorp DE increased its holdings in shares of Allogene Therapeutics by 41.9% during the 2nd quarter. US Bancorp DE now owns 5,474 shares of the company’s stock worth $63,000 after buying an additional 1,616 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Allogene Therapeutics during the 1st quarter worth $66,000. Point72 Hong Kong Ltd increased its holdings in shares of Allogene Therapeutics by 171.1% during the 1st quarter. Point72 Hong Kong Ltd now owns 11,467 shares of the company’s stock worth $104,000 after buying an additional 7,237 shares during the last quarter. InterOcean Capital Group LLC acquired a new stake in shares of Allogene Therapeutics during the 1st quarter worth $109,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Allogene Therapeutics by 13.3% during the 1st quarter. Victory Capital Management Inc. now owns 14,335 shares of the company’s stock worth $120,000 after buying an additional 1,688 shares during the last quarter. 84.81% of the stock is currently owned by institutional investors and hedge funds.

Allogene Therapeutics Price Performance

Shares of Allogene Therapeutics stock opened at $10.02 on Friday. Allogene Therapeutics, Inc. has a 1-year low of $6.43 and a 1-year high of $19.62. The business has a 50-day moving average of $11.26 and a 200-day moving average of $11.36. The company has a market capitalization of $1.44 billion, a PE ratio of -4.55 and a beta of 0.59.

Allogene Therapeutics (NASDAQ:ALLOGet Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same quarter in the previous year, the business earned ($0.57) EPS. On average, equities analysts expect that Allogene Therapeutics, Inc. will post -2.39 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ALLO shares. Raymond James downgraded Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 10th. Truist Financial lowered their price target on Allogene Therapeutics to $29.00 in a report on Tuesday, August 23rd. Oppenheimer lowered their price target on Allogene Therapeutics to $32.00 in a report on Thursday, October 13th. B. Riley lowered their price target on Allogene Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, September 22nd. Finally, JMP Securities reiterated a “buy” rating and issued a $23.00 price target on shares of Allogene Therapeutics in a report on Tuesday, September 27th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.10.

Allogene Therapeutics Company Profile

(Get Rating)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Further Reading

Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics, Inc. (NASDAQ:ALLOGet Rating).

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.